《衡量医药创新回报》系列报告——释放人工智能潜能（英文版）-32页

April2024UnleashAI’spotentialMeasuringthereturnfrompharmaceuticalinnovation–14theditionForeword1Executivesummary2Measuringthereturnfrom4pharmaceuticalinnovationRealisingefficiencyopportunities8Optimisingthevalueofpipelines14Strategiestoimproveproductivity18KeyquestionsforanoptimumR&Dstrategy24Endnotes25Contacts27ContentsForewordWelcometoUnleashAI’spotential,Deloitte’sfourteenthannualreportinourMeasuringthereturnfrompharmaceuticalinnovationseries.Ourreportexplorestheperformanceofthebiopharmaceutical(biopharma)industryanditsabilitytogeneratereturnsfrominvestmentininnovativeproductsinthedevelopmentpipeline.ThecurrentbiopharmaR&Doperatingmodelfacesseveralseriouschallenges,includingongoingregulatorychanges,lossofexclusivityofanunprecedentednumberofhigh-valueassets,andtherapidpaceofscientificandtechnologicaladvancements.However,advancesindigitalisationandartificialintelligence(AI)presentnewopportunitiestoimproveR&Dproductivity,pavingthewayforaneweraofinnovationandacceleratingpatientaccesstonewtherapies.Asalways,ourreportexplorestheindustry’sperformance,thechangingcharacteristicsofthelate-stageportfoliosandtheopportunitiesforbiopharmacompaniestoimprovecapitalreturns.Between2010and2023,ourreportserieshasprovidedinsightsintotheproductivityofbiopharmaR&D.In2010,weanalysedtheexpectedreturnoninvestmentfromthelate-st...